| Publikationstyp: | Beitrag in wissenschaftlicher Zeitschrift |
| Art der Begutachtung: | Peer review (Publikation) |
| Titel: | Challenges with matrix metalloproteinase inhibition and future drug discovery avenues |
| Autor/-in: | Fischer, Thomas Riedl, Rainer |
| et. al: | No |
| DOI: | 10.1080/17460441.2020.1819235 |
| Erschienen in: | Expert Opinion on Drug Discovery |
| Band(Heft): | 16 |
| Heft: | 1 |
| Seite(n): | 75 |
| Seiten bis: | 88 |
| Erscheinungsdatum: | 14-Sep-2020 |
| Verlag / Hrsg. Institution: | Taylor & Francis |
| ISSN: | 1746-0441 1746-045X |
| Sprache: | Englisch |
| Schlagwörter: | Antibodies; Drug design; Drug discovery; Hemopexin-like domain; Matrix metalloproteinase; Medicinal chemistry; Polypharmacology; Small-molecule inhibitors |
| Fachgebiet (DDC): | 615: Pharmakologie und Therapeutik |
| Zusammenfassung: | Matrix metalloproteinases have been in the scope of pharmaceutical drug discovery for decades as promising targets for drug development. Until present, no modulator of the enzyme class survived clinical trials, all failing for various reasons. Nevertheless, the target family did not lose its attractiveness and there is ever more evidence that MMP modulators are likely to overcome the hurdles and result in successful clinical therapies. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/21834 |
| Volltext Version: | Publizierte Version |
| Lizenz (gemäss Verlagsvertrag): | Lizenz gemäss Verlagsvertrag |
| Departement: | Life Sciences und Facility Management |
| Organisationseinheit: | Institut für Chemie und Biotechnologie (ICBT) |
| Enthalten in den Sammlungen: | Publikationen Life Sciences und Facility Management |
Dateien zu dieser Ressource:
Es gibt keine Dateien zu dieser Ressource.
Zur Langanzeige
Fischer, T., & Riedl, R. (2020). Challenges with matrix metalloproteinase inhibition and future drug discovery avenues. Expert Opinion on Drug Discovery, 16(1), 75–88. https://doi.org/10.1080/17460441.2020.1819235
Fischer, T. and Riedl, R. (2020) ‘Challenges with matrix metalloproteinase inhibition and future drug discovery avenues’, Expert Opinion on Drug Discovery, 16(1), pp. 75–88. Available at: https://doi.org/10.1080/17460441.2020.1819235.
T. Fischer and R. Riedl, “Challenges with matrix metalloproteinase inhibition and future drug discovery avenues,” Expert Opinion on Drug Discovery, vol. 16, no. 1, pp. 75–88, Sep. 2020, doi: 10.1080/17460441.2020.1819235.
FISCHER, Thomas und Rainer RIEDL, 2020. Challenges with matrix metalloproteinase inhibition and future drug discovery avenues. Expert Opinion on Drug Discovery. 14 September 2020. Bd. 16, Nr. 1, S. 75–88. DOI 10.1080/17460441.2020.1819235
Fischer, Thomas, and Rainer Riedl. 2020. “Challenges with Matrix Metalloproteinase Inhibition and Future Drug Discovery Avenues.” Expert Opinion on Drug Discovery 16 (1): 75–88. https://doi.org/10.1080/17460441.2020.1819235.
Fischer, Thomas, and Rainer Riedl. “Challenges with Matrix Metalloproteinase Inhibition and Future Drug Discovery Avenues.” Expert Opinion on Drug Discovery, vol. 16, no. 1, Sept. 2020, pp. 75–88, https://doi.org/10.1080/17460441.2020.1819235.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.